help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2004-1535
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saitoh, M.
Right arrow Articles by Kurachi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saitoh, M.
Right arrow Articles by Kurachi, H.
Endocrinology Vol. 146, No. 11 4917-4925
Copyright © 2005 by The Endocrine Society

Medroxyprogesterone Acetate Induces Cell Proliferation through Up-Regulation of Cyclin D1 Expression via Phosphatidylinositol 3-Kinase/Akt/Nuclear Factor-{kappa}B Cascade in Human Breast Cancer Cells

Maki Saitoh, Masahide Ohmichi, Kazuhiro Takahashi, Jun Kawagoe, Tsuyoshi Ohta, Masakazu Doshida, Toshifumi Takahashi, Hideki Igarashi, Akiko Mori-Abe, Botao Du, Seiji Tsutsumi and Hirohisa Kurachi

Department of Obstetrics and Gynecology, Yamagata University, School of Medicine, Yamagata 990-9585, Japan

Address all correspondence and requests for reprints to: Dr. Masahide Ohmichi, Department of Obstetrics and Gynecology, Yamagata University, School of Medicine, 2-2-2 Iidanishi, Yamagata 990-9585, Japan. E-mail: masa{at}med.id.yamagata-u.ac.jp.

The mechanism of medroxyprogesterone acetate (MPA)-induced cell proliferation in human breast cancer cells remains elusive. We examined the mechanism by which MPA affects the cyclin D1 expression in progesterone receptor (PR)-positive T47D human breast cancer cells. MPA (10 nM) treatment for 48 h induced proliferation of the cells (1.6-fold induction). MPA induced cyclin D1 expression (3.3-fold induction), and RU486, a selective PR antagonist, blocked the MPA-induced cell proliferation and cyclin D1 expression (23% inhibition). MPA increased both the protein level (2.2-fold induction) and promoter activity (2.7-fold induction) of cyclin D1 in MCF-7 cells transfected with PRB but not with PRA. Although MPA transcriptionally activated cyclin D1 expression, cyclin D1 promoter does not have progesterone-responsive element-related sequence. We further examined the mechanism for the regulation of the cyclin D1 expression. Because the cyclin D1 promoter contains three putative nuclear factor-{kappa}B (NF{kappa}B)-binding motifs and NF{kappa}B is a substrate of Akt, we investigated the effect of the phosphatidylinositol 3-kinase (PI3K)/Akt/NF{kappa}B cascade on the responses of cyclin D1 to MPA. MPA induced the transient phosphorylation of Akt (2.7-fold induction at 5 min), and treatment with PI3K inhibitor (wortmannin) attenuated the MPA-induced up-regulation of cyclin D1 expression (40% inhibition) and cell proliferation (40% inhibition). MPA also induced phosphorylation of inhibitor of NF{kappa}B{alpha} (I{kappa}B{alpha}) (2.3-fold induction), and treatment with wortmannin attenuated the MPA-induced I{kappa}B{alpha} phosphorylation (60% inhibition). Treatment with an I{kappa}B{alpha} phosphorylation inhibitor (BAY 11-7085) or a specific NF{kappa}B nuclear translocation inhibitor (SN-50) attenuated the MPA-induced up-regulation of both cyclin D1 expression (80 and 50% inhibition, respectively) and cell proliferation (55 and 34% inhibition, respectively). Because MPA induced a transient phosphorylation of Akt and the cyclin D1 promoter contains no progesterone-responsive element-related sequence, the MPA-induced cell proliferation through PRB by up-regulation of cyclin D1 expression via the PI3K/Akt/NF{kappa}B cascade may be a nongenomic mechanism.




This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
I. Quiles, L. Millan-Arino, A. Subtil-Rodriguez, B. Minana, N. Spinedi, C. Ballare, M. Beato, and A. Jordan
Mutational Analysis of Progesterone Receptor Functional Domains in Stable Cell Lines Delineates Sets of Genes Regulated by Different Mechanisms
Mol. Endocrinol., June 1, 2009; 23(6): 809 - 826.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
B. Gellersen, M.S. Fernandes, and J.J. Brosens
Non-genomic progesterone actions in female reproduction
Hum. Reprod. Update, January 1, 2009; 15(1): 119 - 138.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Subtil-Rodriguez, L. Millan-Arino, I. Quiles, C. Ballare, M. Beato, and A. Jordan
Progesterone Induction of the 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Promoter in Breast Cancer Cells Involves Coordinated Recruitment of STAT5A and Progesterone Receptor to a Distal Enhancer and Polymerase Tracking
Mol. Cell. Biol., June 1, 2008; 28(11): 3830 - 3849.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Toualbi-Abed, F. Daniel, M. C. Guller, A. Legrand, J.-L. Mauriz, A. Mauviel, and D. Bernuau
Jun D cooperates with p65 to activate the proximal {kappa}B site of the cyclin D1 promoter: role of PI3K/PDK-1
Carcinogenesis, March 1, 2008; 29(3): 536 - 543.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. R. Daniel, E. J. Faivre, and C. A. Lange
Phosphorylation-Dependent Antagonism of Sumoylation Derepresses Progesterone Receptor Action in Breast Cancer Cells
Mol. Endocrinol., December 1, 2007; 21(12): 2890 - 2906.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
V. Boonyaratanakornkit, E. McGowan, L. Sherman, M. A. Mancini, B. J. Cheskis, and D. P. Edwards
The Role of Extranuclear Signaling Actions of Progesterone Receptor in Mediating Progesterone Regulation of Gene Expression and the Cell Cycle
Mol. Endocrinol., February 1, 2007; 21(2): 359 - 375.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
N. Z. Lu, S. E. Wardell, K. L. Burnstein, D. Defranco, P. J. Fuller, V. Giguere, R. B. Hochberg, L. McKay, J.-M. Renoir, N. L. Weigel, et al.
International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors
Pharmacol. Rev., December 1, 2006; 58(4): 782 - 797.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. R. Gonzalez, S. Cherfils, M. Escobar, J. H. Yoo, C. Carino, A. K. Styer, B. T. Sullivan, H. Sakamoto, A. Olawaiye, T. Serikawa, et al.
Leptin Signaling Promotes the Growth of Mammary Tumors and Increases the Expression of Vascular Endothelial Growth Factor (VEGF) and Its Receptor Type Two (VEGF-R2)
J. Biol. Chem., September 8, 2006; 281(36): 26320 - 26328.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. Benakanakere, C. Besch-Williford, J. Schnell, S. Brandt, M. R. Ellersieck, A. Molinolo, and S. M. Hyder
Natural and Synthetic Progestins Accelerate 7,12-Dimethylbenz[a]Anthracene-Initiated Mammary Tumors and Increase Angiogenesis in Sprague-Dawley Rats.
Clin. Cancer Res., July 1, 2006; 12(13): 4062 - 4071.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society